OraSure Technologies, Inc. EP3.F Stock
OraSure Technologies, Inc. Price Chart
OraSure Technologies, Inc. EP3.F Financial and Trading Overview
OraSure Technologies, Inc. stock price | 4.4 EUR |
Previous Close | 5 EUR |
Open | 4.94 EUR |
Bid | 4.94 EUR x N/A |
Ask | 5.05 EUR x N/A |
Day's Range | 4.94 - 4.94 EUR |
52 Week Range | 2.54 - 6.7 EUR |
Volume | 315 EUR |
Avg. Volume | 5 EUR |
Market Cap | 361.92M EUR |
Beta (5Y Monthly) | 0.096126 |
PE Ratio (TTM) | 12.666667 |
EPS (TTM) | 0.28 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.4 EUR |
EP3.F Valuation Measures
Enterprise Value | 277.01M EUR |
Trailing P/E | 12.666667 |
Forward P/E | 23.523811 |
PEG Ratio (5 yr expected) | 28.4 |
Price/Sales (ttm) | 0.76235425 |
Price/Book (mrq) | 0.918045 |
Enterprise Value/Revenue | 0.584 |
Enterprise Value/EBITDA | 5.444 |
Trading Information
OraSure Technologies, Inc. Stock Price History
Beta (5Y Monthly) | 0.096126 |
52-Week Change | 93.60% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6.7 EUR |
52 Week Low | 2.54 EUR |
50-Day Moving Average | 5.6 EUR |
200-Day Moving Average | 4.89 EUR |
EP3.F Share Statistics
Avg. Volume (3 month) | 5 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 73.26M |
Float | 65.88M |
Short Ratio | N/A |
% Held by Insiders | 4.09% |
% Held by Institutions | 83.64% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 6.15% |
Operating Margin (ttm) | 7.49% |
Gross Margin | 39.84% |
EBITDA Margin | 10.71% |
Management Effectiveness
Return on Assets (ttm) | 4.96% |
Return on Equity (ttm) | 7.70% |
Income Statement
Revenue (ttm) | 474.74M EUR |
Revenue Per Share (ttm) | 6.53 EUR |
Quarterly Revenue Growth (yoy) | 128.90% |
Gross Profit (ttm) | 147.64M EUR |
EBITDA | 50.89M EUR |
Net Income Avi to Common (ttm) | 29.23M EUR |
Diluted EPS (ttm) | 0.39 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 112.37M EUR |
Total Cash Per Share (mrq) | 1.53 EUR |
Total Debt (mrq) | 12.09M EUR |
Total Debt/Equity (mrq) | 3.07 EUR |
Current Ratio (mrq) | 6.233 |
Book Value Per Share (mrq) | 5.381 |
Cash Flow Statement
Operating Cash Flow (ttm) | -5379000 EUR |
Levered Free Cash Flow (ttm) | -46179248 EUR |
Profile of OraSure Technologies, Inc.
Country | Germany |
State | PA |
City | Bethlehem |
Address | 220 East First Street |
ZIP | 18015 |
Phone | 610 882 1820 |
Website | https://www.orasure.com |
Industry | Medical Instruments & Supplies |
Sector(s) | Healthcare |
Full Time Employees | 840 |
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's diagnostic products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgeneGUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Q&A For OraSure Technologies, Inc. Stock
What is a current EP3.F stock price?
OraSure Technologies, Inc. EP3.F stock price today per share is 4.4 EUR.
How to purchase OraSure Technologies, Inc. stock?
You can buy EP3.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for OraSure Technologies, Inc.?
The stock symbol or ticker of OraSure Technologies, Inc. is EP3.F.
Which industry does the OraSure Technologies, Inc. company belong to?
The OraSure Technologies, Inc. industry is Medical Instruments & Supplies.
How many shares does OraSure Technologies, Inc. have in circulation?
The max supply of OraSure Technologies, Inc. shares is 74.41M.
What is OraSure Technologies, Inc. Price to Earnings Ratio (PE Ratio)?
OraSure Technologies, Inc. PE Ratio is 15.71428600 now.
What was OraSure Technologies, Inc. earnings per share over the trailing 12 months (TTM)?
OraSure Technologies, Inc. EPS is 0.28 EUR over the trailing 12 months.
Which sector does the OraSure Technologies, Inc. company belong to?
The OraSure Technologies, Inc. sector is Healthcare.